Cancer
Sodium-Glucose Cotransporter-2 Inhibitors Show Promise in Reducing Cardiovascular Events and Mortality in Cancer Patients
Researchers from Zanjan University of Medical Science have conducted a systematic review and meta-analysis to investigate the effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on patients with cancer and diabetes undergoing cardiotoxic cancer treatment. The study, published in Cardio-Oncology, found that SGLT2 inhibitors significantly reduced mortality, heart failure hospitalization, arrhythmia, and